Nachrichten zur Bristol-Myers Squibb Co. Aktie

Bristol Myers Squibb EPS beats by $0.16, beats on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ABIO To Start Phase 2 COVID-19 Trial In Q4, ACIU On Track, BCLI Expects ALS Trial Data In Nov.

Todays Daily Dose brings you news about ARCA biopharmas progress in its COVID-19 drug candidate, AC Immune upcoming milestones, BrainStorm…

Bristol-Myers, Pfizer stocks rise on blood-thinner patent win

Bristol-Myers Squibb Co. shares rallied in the extended session Wednesday after a federal judge ruled for it and Pfizer…

Bristol Myers Squibb Q2 2020 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb Reports Earnings Tomorrow

Bristol-Myers is trading at 8.5 times earnings expected over the next 12 months, according to FactSet, well below its average…

Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020…

Is Bristol Myers Squibb Stock a Buy?

Heres why choosing this pharma stock amid the coronavirus crisis could be the wisest decision you make this year....…

Bristol-Myers, CVS, Disney, Uber and More Major Earnings Coming This Week

Um den gesamten Artikel unter feedproxy.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb NDA, And Other News: The Good, Bad And Ugly Of Biopharma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Top Analyst Upgrades and Downgrades: ADM, Beyond Meat, Bristol-Myers, Carvana, CRISPR, FirstEnergy, Peloton, Shopify, Tesla, Uber, Visa and More

Um den gesamten Artikel unter feedproxy.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $59.46, marking a -1.54% move from the previous day....…

If You Invested $1,000 in Bristol Myers Squibb During The Last Recession, This Is How Much You Would Have Today

How much has this healthcare stock returned since 2008?...…

Is Bristol Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "

Bristol Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market....…

EMA accepts Bristol Myers Squibb CAR T application for lymphoma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $57.75, marking a +0.56% move from the previous day....…

Bristol Myers (BMY) Moves to Strong Buy: Rationale Behind the Upgrade

Bristol Myers (BMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the companys earnings…

Is Bristol-Myers Squibb A Better Bet Than Amgen?

Bristol-Myers Squibbs stock has declined 2% since early February after the WHO declared the coronavirus a global health emergency, while…

The Zacks Analyst Blog Highlights: Alibaba, NVIDIA, Bristol Myers Squibb, PetroChina and S&P Global

The Zacks Analyst Blog Highlights: Alibaba, NVIDIA, Bristol Myers Squibb, PetroChina and S&P Global...…

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

Bristol Myers Squibb (BMY) closed at $60.29 in the latest trading session, marking a +0.17% move from the prior day....…

Top Stock Reports for Alibaba, NVIDIA & Bristol Myers Squibb

Top Stock Reports for Alibaba, NVIDIA & Bristol Myers Squibb...…

Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners

Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners...…

Dragonfly Therapeutics kündigt neue Forschungskooperation mit Bristol Myers Squibb an, um neuartige Arzneimittelkandidaten zu entwickeln, die auf die Behandlung von Multipler Sklerose und Neuroinflammation abzielen

Dragonfly Therapeutics, Inc.: Waltham, Massachusetts (ots/PRNewswire) - Dragonfly weitet die bestehende Zusammenarbeit mit Bristol Myers Squibb in den Feldern Onkologie…

Bristol-Myers Squibb: Growth And Valuation Trump Other Concerns

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb: Insider Anticipating Significant Shareholder Value Creation From Merger

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

DIVIDEND/INTEREST INFORMATION - 02.07.2020 - 2

FOLGENDE WERTPAPIERE WERDEN AM 02.07.2020 EX DIVIDENDE/ZINSEN GEHANDELT. THE EX-DIVIDEND/INTEREST DAY OF THE FOLLOWING SHARES WILL BE 02.07.2020. INSTR EXCH…

XETR : INSTRUMENT_EVENT BRM

DIVIDEND/INTEREST INFORMATION - 02.07.2020;Das Instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY wird ex Dividende/Zinsen gehandelt am 02.07.2020 The instrument BRM US1101221083…

Is Bristol Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "

Bristol Myers (BMY) could produce exceptional returns because of its solid growth attributes....…

DIVIDEND/INTEREST INFORMATION - 02.07.2020 - 1

FOLGENDE WERTPAPIERE WERDEN AM 01.07.2020 CUM DIVIDENDE/ZINSEN UND AM 02.07.2020 EX DIVIDENDE/ZINSEN GEHANDELT. THE PRE-DIVIDEND/INTEREST DAY OF THE FOLLOWING SHARES WILL…

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.80, marking a +1.73% move from the previous day....…

Morning Bell With Jim Cramer: Buy Bristol Myers Over Gilead

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Is Bristol Myers Squibb (BMY) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

Bristol Myers & Acceleron Obtain EC Approval for Reblozyl

Bristol Myers (BMY) and partner Acceleron win EC approval of Reblozyl (luspatercept) for two indications....…

Better Buy: Amgen vs. Bristol Myers Squibb

Heres how these two drugmakers stack up against each other....…

5 Reasons Bristol Myers Squibb Is An Exceptional Blue-Chip For Retirees

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Special Call (Transcript)

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb (BMY) Investor Series - Immunology & Cardiovascular - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Hosts Investor Series - Hematology Conference Call (Transcript)

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

3 Reasons Bristol-Myers Squibb Could Make You Rich

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Is Everyone Talking About Bristol Myers Squibb Stock?

Heres why this cheap blue-chip pharma stock is a solid buy for dividend, value, and growth investors alike....…

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.38, marking a +1.42% move from the previous day....…

Bristol Myers Squibb Offers Growth With A Safe Dividend

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy? (Revised)

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Kitov Pharma +49% on collaboration with Bristol Myers for lung cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

CytomX Therapeutics Announces Preclinical Data from Anti-CTLA-4 Probody Therapeutic Programs Presented by Partner Bristol Myers Squibb at AACR Annual Meeting

Preclinical Data Supports Expanded Therapeutic Index and Provides Rationale for Ongoing Clinical Studies Preclinical Data Supports Expanded Therapeutic Index and…